Warren R, Conrad C, Foley P, Iversen L, Langley R, Kokolakis G, Davis L, Vanvoorden V, Wiegratz S, Merola J. Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. J of Skin [Internet]. 2022Nov.16 [cited 2024Jul.22];6(6):s70. Available from: https://jofskin.org/index.php/skin/article/view/1826